Bradanicline
Clinical data | |
---|---|
Other names | TC-5619 |
Identifiers | |
| |
JSmol) | |
| |
(verify) |
Bradanicline (
clinical trials were completed successfully, and it was in phase II trials.[3]
In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013.[7] It was also discontinued for ADHD.[7]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73" (PDF). World Health Organization. pp. 68–9. Retrieved 3 January 2017.
- ^ "TC-5619 Cognitive Dysfunction in Schizophrenia". Catalyst Biosciences. Archived from the original on August 20, 2008.
- .
- ^ "Targacept retains full development rights for TC-5619". Fierce Biotech. 2 May 2011.
- ^ "Targacept ends development of ADHD drug". Market Watch.
- ^ "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). November 27, 2013.
- ^ a b "Bradanicline - Attenua". AdisInsight. Springer Nature Switzerland AG.